Terms: = Bone cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
21 results:
1. Design, synthesis, and in-silico study of novel triarylethylene analogs with dual anti-estrogenic and serotonergic activity.
Mostafa T; Albeir M; Wober J; Abadi A; Salama I; Ahmed NS
Drug Dev Res; 2024 Feb; 85(1):e22127. PubMed ID: 37877739
[TBL] [Abstract] [Full Text] [Related]
2. Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing.
Golubenko EO; Savelyeva MI; Sozaeva ZA; Korennaya VV; Poddubnaya IV; Valiev TT; Kondratenko SN; Ilyin MV
Drug Metab Pers Ther; 2023 Dec; 38(4):339-347. PubMed ID: 37466310
[TBL] [Abstract] [Full Text] [Related]
3. Enzalutamide Reduces Oxycodone Exposure in Men with Prostate cancer.
Detert Oude Weme SEH; Hulskotte LMG; Vervenne WL; Imholz ALT; Cremers RGHM; Taxis K; Reyners AKL; van Berlo-van de Laar IRF; Jansman FGA; Benoist GE
Clin Pharmacokinet; 2023 Jul; 62(7):989-996. PubMed ID: 37162620
[TBL] [Abstract] [Full Text] [Related]
4. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract] [Full Text] [Related]
5. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
Jayaraman S; Reid JM; Hawse JR; Goetz MP
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
[TBL] [Abstract] [Full Text] [Related]
6. Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response.
Carr DF; Turner RM; Pirmohamed M
Br J Clin Pharmacol; 2021 Feb; 87(2):237-255. PubMed ID: 32501544
[TBL] [Abstract] [Full Text] [Related]
7. Genetic associations of docetaxel-based chemotherapy-induced myelosuppression in Chinese Han population.
Ren W; Zhou C; Liu Y; Su K; Jia L; Chen L; Li M; Ma J; Zhou W; Zhang S; Zhang D; Cong Z; Niu X; Zhang S; Shen L; Huai C; Sun X; Li G; Qin S; Guo L
J Clin Pharm Ther; 2020 Apr; 45(2):354-364. PubMed ID: 31778586
[TBL] [Abstract] [Full Text] [Related]
8. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast cancer: Lessons Learnt from Tamoxifen and cyp2d6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract] [Full Text] [Related]
9. [Ovarian Ablation in Breast cancer Patients and the Possibility of Influencing Treatment Side Effects].
Palácová M
Klin Onkol; 2016; 29 Suppl 3():S29-38. PubMed ID: 28118722
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of endometrial thickness and bone mineral density based on cyp2d6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment.
Günaldı M; Erkisi M; Afşar CU; Erçolak V; Paydas S; Kara IO; Sahin B; Gulec UK; Secilmis A
Pharmacology; 2014; 94(3-4):183-9. PubMed ID: 25378122
[TBL] [Abstract] [Full Text] [Related]
11. Toremifene for breast cancer: a review of 20 years of data.
Vogel CL; Johnston MA; Capers C; Braccia D
Clin Breast Cancer; 2014 Feb; 14(1):1-9. PubMed ID: 24439786
[TBL] [Abstract] [Full Text] [Related]
12. Individualization of treatment strategies.
Fernández Ortega A; Jolis López L; Viñas Villaró G; Villanueva Vázquez R; García Arias A; González Farré X; González Jiménez S; Saura Manich C; Cortés Castán J
Adv Ther; 2011 Sep; 28 Suppl 6():19-38. PubMed ID: 21922393
[TBL] [Abstract] [Full Text] [Related]
13. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.
Kim J; Peraire C; Solà J; Johanning KM; Dalton JT; Veverka KA
Xenobiotica; 2011 Oct; 41(10):851-62. PubMed ID: 21726172
[TBL] [Abstract] [Full Text] [Related]
14. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
[TBL] [Abstract] [Full Text] [Related]
15. Clinical aspects of pharmacogenetics of pain and co-morbidities of emotional distress.
Kamen BA
Asian Pac J Cancer Prev; 2010; 11 Suppl 1():27-30. PubMed ID: 20590345
[TBL] [Abstract] [Full Text] [Related]
16. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.
Henry NL; Nguyen A; Azzouz F; Li L; Robarge J; Philips S; Cao D; Skaar TC; Rae JM; Storniolo AM; Flockhart DA; Hayes DF; Stearns V
Br J Cancer; 2010 Jan; 102(2):294-300. PubMed ID: 19953095
[TBL] [Abstract] [Full Text] [Related]
17. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract] [Full Text] [Related]
18. Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Bonanni B; Serrano D; Gandini S; Guerrieri-Gonzaga A; Johansson H; Macis D; Cazzaniga M; Luini A; Cassano E; Oldani S; Lien EA; Pelosi G; Decensi A
Clin Cancer Res; 2009 Nov; 15(22):7053-60. PubMed ID: 19887477
[TBL] [Abstract] [Full Text] [Related]
19. Genetic polymorphisms of cyp2d6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
[TBL] [Abstract] [Full Text] [Related]
20. Clinical implications of cyp2d6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.
Lim HS; Ju Lee H; Seok Lee K; Sook Lee E; Jang IJ; Ro J
J Clin Oncol; 2007 Sep; 25(25):3837-45. PubMed ID: 17761971
[TBL] [Abstract] [Full Text] [Related]
[Next]
